Phaseline

Companies › Shanghai Kechow Pharma

Shanghai Kechow Pharma: clinical trials, targets and expected readouts

4 active drug programs in 10 registered trials: 5 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vemurafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 3Colorectal Cancer MetastaticDec 2026
tunlametinib
MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation …Dec 2026
HL-085–Phase 2Neurofibromatosis 1Oct 2028
HL-003–Phase 1Healthy Subjects–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06867393HL-003Phase 1Healthy SubjectsOtherAug 2025
NCT06008119tunlametinibPhase 3Colorectal Cancer MetastaticOncologyDec 2026
NCT06008119VemurafenibPhase 3Colorectal Cancer MetastaticOncologyDec 2026
NCT06970353tunlametinibPhase 2Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationOncologyDec 2026
NCT06970353tunlametinibPhase 2Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationOncologyDec 2026
NCT06008106tunlametinibPhase 3MelanomaOncologySep 2027
NCT07170293tunlametinibPhase 2Solid CancersOncologySep 2027
NCT07445022tunlametinibPhase 4Melanoma AdvancedOncologySep 2028
NCT05331105HL-085Phase 2Neurofibromatosis 1OncologyOct 2028
NCT07750067tunlametinibPhase 2Melanoma MetastaticOncologyJul 2030

Targets

MAP2K1 (1) MAP2K2 (1) BRAF (1)

Companies with the same targets

Roche Pfizer Pierre Fabre Medicament Novartis Hanmi Pharmaceutical Company AstraZeneca Pasithea Therapeutics Merck KGaA SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Verastem

Companies built like this

Pierre Fabre Medicament SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Fore Biotherapeutics Day One Biopharmaceuticals Immuneering

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.